Call Text Chat Email Refer a Patient Join a Study

Search

MotherToBaby

Medications and More during pregnancy and breastfeeding

Human papillomavirus (HPV) Vaccine

Selected References:

  • American College of Obstetricians and Gynecologists. 2013. ACOG committee opinion no. 558: Integrating immunizations into practice. Obstet Gynecol 121(4):897-903. 
  • Angelo MG, et al. 2014. Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme. Pharmacoepidemiol Drug Saf. 23(5):466-79.  
  • Baril L, et al. 2015. Risk of spontaneous abortion and other pregnancy outcomes in 15-25 year old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom. Vaccine 33(48):6884-91. 
  • Bukowinski AT, et al. 2020. Maternal and infant outcomes following exposure to quadrivalent human papillomavirus vaccine during pregnancy. Vaccine. 18;38(37):5933-5939.  
  • Centers for Disease Control and Prevention. 2025. Human Papillomavirus (HPV) Vaccine Safety. Available at https://www.cdc.gov/vaccine-safety/vaccines/hpv.html   
  • Chen W, et al. 2019. Safety of a quadrivalent human papillomavirus vaccine in a Phase 3, randomized, double-blind, placebo-controlled clinical trial among Chinese women during 90 months of follow-up. Vaccine 37(6):889-97.  
  • Dousti R, Allahqoli L, Ayar Kocaturk A, Hakimi S. 2023. Can human papillomavirus vaccination during pregnancy result in miscarriage and stillbirth? A meta-analysis and systematic review. Eur J Midwifery. 2023;7:9.  
  • Faber MT, et al 2019. Adverse pregnancy outcomes and infant mortality after quadrivalent HPV vaccination during pregnancy. Vaccine 37(2)265-271. 
  • Garland SM, et al. 2009. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol 114(6):1179-1188.  
  • Garolla A et. Al. 2013. Sperm viral infection and male infertility: focus on HBV, HCV, HIV, HPV, HSV, HCMV, and AAV. J Reprod Immunol 100(1):20-9.  
  • Goss MA, et al. 2015. Final report on exposure during pregnancy from a pregnancy registry for quadrivalent human papillomavirus vaccine. Vaccine 33(29): 3422-3428. 
  • Forbes N, Montroy J, Salvadori MI, Dubey V. 2024. Summary of the National Advisory Committee on Immunization (NACI) Statement: Updated guidance on human papillomavirus (HPV) vaccines. Can Commun Dis Rep. 50(12):419-425.  
  • Kharbanda EO, et al. 2018. Risk of spontaneous abortion after inadvertent human papillomavirus vaccination in pregnancy. Obstet Gynecol 132:34-44. 
  • Kharbanda EO, et al. 2021. Association of Inadvertent 9-Valent Human Papillomavirus Vaccine in Pregnancy With Spontaneous Abortion and Adverse Birth Outcomes. JAMA Netw Open 4(4): e214340. 
  • Landazabal CS, et al. 2019. Safety of 9- valent human papillomavirus vaccine administration among pregnant women: Adverse event reports in the Vaccine Adverse Event Reporting System (VAERS), 2014-2017. Vaccine 37:1229-1234. 
  • Lawton B, et al. 2018. Association of prior HPV vaccinations with reduced preterm birth: a population based study. Vaccine 36: 134-140. 
  • Lipkind HS, et al. 2017. Maternal and infant outcomes after human papillomavirus vaccination in the periconceptional period or during pregnancy. Obstet Gynecol; 130(3):599-608.  
  • Mammas IN, et al. 2011. Can ‘high-risk’ human papillomaviruses (HPVs) be detected in human breast milk? Acta Paediatr 100(5):705-7. 
  • Markowitz LE, et al. 2007. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 56 (RR-2):1-24.  
  • Matys K, et al. 2012. Mother-infant transfer of anti-human papillomavirus (HPV) antibodies following vaccination with the quadrivalent HPV (type 6/11/16/18) virus-like particle vaccine. Clin Vaccine Immunol Jun; 19(6):881-5.  
  • McDonnold M, et al. 2014. High risk human papillomavirus at entry to prenatal care and risk of preeclampsia. Am J Obstet Gynecol 210(2):138.e1-5. 
  • Moreira ED, E et al. 2016. Safety profile of the 9-valent HPV vaccine: A combined analysis of 7 phase III clinical trials. Pediatrics. 138(2):e20154387. 
  • Muscianisi F, Foresta C, Garolla A. Role of HPV vaccination for prevention of male infertility. Minerva Endocrinol (Torino). 2022 Mar;47(1):70-76.  
  • Panagiotou OA, et al. 2015. Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV Vaccine Trial. BMJ 7; 351:h4358.  
  • Segal L, et al. 2011. Evaluation of the intramuscular administration of Cervarix vaccine on fertility, pre- and post-natal development in rats. Reprod Toxicol 31(1):111-20.  
  • Scheller NM, et al. 2017. Quadrivalent HPV vaccination and the risk of adverse pregnancy outcomes. N Engl J Med 376:1223-1233. 
  • Wacholder S, et al. 2010. Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomized clinical trials. BMJ 340:C712.  
  • Wang A, et al. 2020. Pregnancy Outcomes After Human Papillomavirus Vaccination in Periconceptional Period or During Pregnancy: A Systematic Review and Meta-analysis. Hum Vaccin Immunother. 3;16(3):581-589.  
  • Wise LD, et al. 2008. Lack of effects on fertility and developmental toxicity of a quadrivalent HPV vaccine in Sprague-Dawley rats. Birth Defects Res (B) 83:561-572. 
  • Yan X, Li H, Song B, et al. 2023. Association of periconceptional or pregnancy exposure of HPV vaccination and adverse pregnancy outcomes: A systematic review and meta-analysis with trial sequential analysis. Front Pharmacol. 2023;14:1181919  
  • Zhang J, Lian Z, Xue X, et al. 2024. Does HPV vaccination during periconceptional or gestational period increase the risk of adverse pregnancy outcomes?-An updated systematic review and meta-analysis based on timing of vaccination. Acta Obstet Gynecol Scand. 103(10):1943-1954.  

 

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,000,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.